Harte-Hanks launches health and wellness agency True

Share this article:
Harte-Hanks launches health and wellness agency True
Harte-Hanks launches health and wellness agency True
Harte-Hanks, the direct marketing giant, is looking to break off a piece of the burgeoning health and wellness market with the launch of True Health + Wellness.

The shop, launching with a staff of 20-40 and business from existing clients, will be co-located with the company's consumer CRM shop, The Agency Inside Harte-Hanks, in Yardley, PA, and will be headed by managing director Anne Stroup and creative director Anthony Rotolo. Stroup was previously head of the pharma division at The Agency Inside Harte Hanks, while Rotolo was previously an EVP, creative director at Draftfcb Healthcare.

The launch is an effort to expand beyond the company's heritage in digital and CRM, Stroup told MM&M.

“What we're offering is a full-service brand advertising agency,” Stroup said. “We've always been in health and wellness, we've been in pharmaceutical, but we see pharma moving into this customer-centric model, and we've identified a gap in the available agency services to take the brand and make it relevant on the individual level.”  

By housing True Health + Wellness with The Agency Inside Harte-Hanks, Stroup said the healthcare shop will be able to leverage learnings from its larger consumer CRM sibling and adapt them to the pharma regulatory environment.

With a staff of around 200, The Agency Inside Harte-Hanks handles clients from the automotive, financial services and consumer packaged good sectors.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.